Overview

New Treatment of Alopecia Areata

Status:
Completed
Trial end date:
2022-10-19
Target enrollment:
Participant gender:
Summary
Abstract: Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss. Methods: our study included 40 patients from may 2019 to july 2022 diagnosed clinically, dermatoscopically and pathologically as alopecia areata Data were enrolled from department of dermatology and venereology, Al-Hussein hospital.
Phase:
N/A
Details
Lead Sponsor:
Al-Azhar University